A prospective, randomized, open-label trial of early versus late povidone-iodine gargling in patients with COVID-19

DOI record: { "DOI": "10.1038/s41598-022-24683-8", "ISSN": [ "2045-2322" ], "URL": "http://dx.doi.org/10.1038/s41598-022-24683-8", "abstract": "<jats:title>Abstract</jats:title><jats:p>Povidone-iodine (PVP–I) is a broad-spectrum antiseptic reagent that has been used for over 50 years. The purpose of this study is to look into the effect of gargling with PVP–I gargling on virus clearance and saliva infectivity in COVID-19. A prospective, randomized, open-label trial of intervention with PVP–I was conducted at three quarantine facilities in Osaka, Japan, enrolling adolescents and adults with asymptomatic-to-mild COVID-19. Patients were randomly allocated to the early and late intervention group at a 1:1 ratio. The early group gargled with PVP–I from days 2 to day 6; the late group gargled with water first, then with PVP–I from day 5 after sampling till day 6. The primary and secondary endpoints were viral clearance for SARS-CoV-2 using RT-qPCR at days 5 and 6, respectively, and the investigational endpoint was saliva infectivity clearance on day5. We enrolled 430 participants, with 215 assigned to each group, and 139 in the early group and 140 in the late had a positive saliva RT-qPCR test on day 2. On day 5, the early group had a significantly higher RT-qPCR negative rate than that of the late group (p = 0.015), and the early had a significantly higher clearance rate of infectivity (p = 0.025). During the PVP–I intervention, one participant reported oropharyngeal discomfort. Gargling with PVP–I may hasten virus clearance and reduce viral transmission via salivary droplets and aerosols in patients with asymptomatic-to-mild COVID-19. (Clinical trial registration numbers: jRCT1051200078 and dateof registration: 24/11/2020).</jats:p>", "alternative-id": [ "24683" ], "article-number": "20449", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "29 July 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "18 November 2022" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "28 November 2022" }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 1, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Matsuyama", "given": "Akifumi", "sequence": "first" }, { "affiliation": [], "family": "Okura", "given": "Hanayuki", "sequence": "additional" }, { "affiliation": [], "family": "Hashimoto", "given": "Shyoji", "sequence": "additional" }, { "affiliation": [], "family": "Tanaka", "given": "Toshio", "sequence": "additional" } ], "container-title": "Scientific Reports", "container-title-short": "Sci Rep", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2022, 11, 28 ] ], "date-time": "2022-11-28T11:05:01Z", "timestamp": 1669633501000 }, "deposited": { "date-parts": [ [ 2022, 11, 29 ] ], "date-time": "2022-11-29T02:20:17Z", "timestamp": 1669688417000 }, "indexed": { "date-parts": [ [ 2022, 11, 29 ] ], "date-time": "2022-11-29T05:51:54Z", "timestamp": 1669701114182 }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2022, 11, 28 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2022, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 11, 28 ] ], "date-time": "2022-11-28T00:00:00Z", "timestamp": 1669593600000 } }, { "URL": "https://creativecommons.org/licenses/by/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 11, 28 ] ], "date-time": "2022-11-28T00:00:00Z", "timestamp": 1669593600000 } } ], "link": [ { "URL": "https://www.nature.com/articles/s41598-022-24683-8.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-022-24683-8", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.nature.com/articles/s41598-022-24683-8.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1038", "published": { "date-parts": [ [ 2022, 11, 28 ] ] }, "published-online": { "date-parts": [ [ 2022, 11, 28 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1038/s41591-021-01296-8", "author": "N Huang", "doi-asserted-by": "publisher", "first-page": "892", "issue": "5", "journal-title": "Nat. Med.", "key": "24683_CR1", "unstructured": "Huang, N. et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat. Med. 27(5), 892–903 (2021).", "volume": "27", "year": "2021" }, { "DOI": "10.1038/s41368-020-0080-z", "author": "R Xu", "doi-asserted-by": "publisher", "first-page": "11", "issue": "1", "journal-title": "Int. J. Oral Sci.", "key": "24683_CR2", "unstructured": "Xu, R. et al. Saliva: Potential diagnostic value and transmission of 2019-nCoV. Int. J. Oral Sci. 12(1), 11 (2020).", "volume": "12", "year": "2020" }, { "DOI": "10.1016/j.jhin.2021.04.004", "author": "MV Mateos-Moreno", "doi-asserted-by": "publisher", "first-page": "30", "journal-title": "J. Hosp. Infect.", "key": "24683_CR3", "unstructured": "Mateos-Moreno, M. V., Mira, A., Ausina-Márquez, V. & Ferrer, M. D. Oral antiseptics against coronavirus: In-vitro and clinical evidence. J. Hosp. Infect. 113, 30–43 (2021).", "volume": "113", "year": "2021" }, { "author": "H Kariwa", "first-page": "105", "issue": "3", "journal-title": "Jpn. J. Vet. Res.", "key": "24683_CR4", "unstructured": "Kariwa, H., Fujii, N. & Takashima, I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents. Jpn. J. Vet. Res. 52(3), 105–112 (2004).", "volume": "52", "year": "2004" }, { "DOI": "10.1007/s40121-015-0091-9", "author": "M Eggers", "doi-asserted-by": "publisher", "first-page": "491", "issue": "4", "journal-title": "Infect. Dis. Ther.", "key": "24683_CR5", "unstructured": "Eggers, M., Eickmann, M. & Zorn, J. Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA). Infect. Dis. Ther. 4(4), 491–501 (2015).", "volume": "4", "year": "2015" }, { "DOI": "10.1007/s40121-020-00316-3", "author": "DE Anderson", "doi-asserted-by": "publisher", "first-page": "669", "issue": "3", "journal-title": "Infect. Dis. Ther.", "key": "24683_CR6", "unstructured": "Anderson, D. E. et al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect. Dis. Ther. 9(3), 669–675 (2020).", "volume": "9", "year": "2020" }, { "DOI": "10.1111/odi.13526", "author": "L Martínez Lamas", "doi-asserted-by": "publisher", "journal-title": "Oral Dis.", "key": "24683_CR7", "unstructured": "Martínez Lamas, L. et al. Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. https://doi.org/10.1111/odi.13526 (2020).", "year": "2020" }, { "DOI": "10.1007/s15010-020-01563-9", "author": "CJ Seneviratne", "doi-asserted-by": "publisher", "first-page": "305", "issue": "2", "journal-title": "Infection", "key": "24683_CR8", "unstructured": "Seneviratne, C. J. et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: Randomized control trial in Singapore. Infection 49(2), 305–311 (2021).", "volume": "49", "year": "2021" }, { "DOI": "10.1007/s40121-018-0200-7", "author": "M Eggers", "doi-asserted-by": "publisher", "first-page": "249", "issue": "2", "journal-title": "Infect. Dis. Ther.", "key": "24683_CR9", "unstructured": "Eggers, M., Koburger-Janssen, T., Eickmann, M. & Zorn, J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens. Infect. Dis. Ther. 7(2), 249–259 (2018).", "volume": "7", "year": "2018" }, { "DOI": "10.1111/jopr.13209", "author": "AS Bidra", "doi-asserted-by": "publisher", "first-page": "529", "issue": "6", "journal-title": "J. Prosthodont.", "key": "24683_CR10", "unstructured": "Bidra, A. S. et al. Rapid in-vitro inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using povidone-iodine oral antiseptic rinse. J. Prosthodont. 29(6), 529–533 (2020).", "volume": "29", "year": "2020" }, { "DOI": "10.1016/j.joen.2020.03.008", "author": "A Ather", "doi-asserted-by": "publisher", "first-page": "584", "issue": "5", "journal-title": "J. Endod.", "key": "24683_CR11", "unstructured": "Ather, A., Patel, B., Ruparel, N. B., Diogenes, A. & Hargreaves, K. M. Coronavirus Disease 19 (COVID-19): Implications for clinical dental care. J. Endod. 46(5), 584–595 (2020).", "volume": "46", "year": "2020" }, { "DOI": "10.21203/rs.3.rs-1121993/v1", "author": "B Killingley", "doi-asserted-by": "publisher", "journal-title": "Nat. Med.", "key": "24683_CR12", "unstructured": "Killingley, B. et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge. Nat. Med. https://doi.org/10.21203/rs.3.rs-1121993/v1 (2022).", "year": "2022" }, { "DOI": "10.1159/000246034", "author": "K Nobukuni", "doi-asserted-by": "publisher", "first-page": "69", "issue": "Suppl 2", "journal-title": "Dermatology", "key": "24683_CR13", "unstructured": "Nobukuni, K. et al. The influence of long-term treatment with povidone-iodine on thyroid function. Dermatology 195(Suppl 2), 69–72 (1997).", "volume": "195", "year": "1997" }, { "DOI": "10.1016/j.amjoto.2020.102880", "author": "MM Khan", "doi-asserted-by": "publisher", "first-page": "102880", "issue": "2", "journal-title": "Am. J. Otolaryngol.", "key": "24683_CR14", "unstructured": "Khan, M. M. & Parab, S. R. Tolerability and usability of 0.5% PVP-I gargles and nasal drops in 6692 patients: Observational study. Am. J. Otolaryngol. 42(2), 102880 (2021).", "volume": "42", "year": "2021" }, { "key": "24683_CR15", "unstructured": "ADA releases interim guidance on minimizing COVID-19 transmission risk when treating dental emergencies. https://www.ada.org/en/publications/ada-news/2020-archive/april/ada-releases-interim-guidance-on-minimizing-covid-19-transmission-risk-when-treating-emergencies (2022)." }, { "key": "24683_CR16", "unstructured": "Risk Management Principles for Dentistry. Resource outlining how to apply evidence-informed infection control measures within a broader risk-based approach. https://www.ada.org.au/Covid-19-Portal/Files/pdf/COVID-19-Risk-Management-Guidance.aspx (2022)." }, { "author": "MJ Burton", "first-page": "CD013626", "journal-title": "Cochrane Database Syst. Rev.", "key": "24683_CR17", "unstructured": "Burton, M. J. et al. Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection. Cochrane Database Syst. Rev. 9, CD013626 (2020).", "volume": "9", "year": "2020" }, { "author": "MJ Burton", "first-page": "CD013627", "journal-title": "Cochrane Database Syst. Rev.", "key": "24683_CR18", "unstructured": "Burton, M. J. et al. Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them. Cochrane Database Syst. Rev. 9, CD013627 (2020).", "volume": "9", "year": "2020" }, { "DOI": "10.1016/j.ijid.2021.04.035", "author": "RCS Seet", "doi-asserted-by": "publisher", "first-page": "314", "journal-title": "Int. J. Infect. Dis.", "key": "24683_CR19", "unstructured": "Seet, R. C. S. et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. Int. J. Infect. Dis. 106, 314–322 (2021).", "volume": "106", "year": "2021" }, { "DOI": "10.1073/pnas.2104547118", "author": "Q Yang", "doi-asserted-by": "publisher", "issue": "21", "journal-title": "Proc. Natl. Acad. Sci. USA", "key": "24683_CR20", "unstructured": "Yang, Q. et al. Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities. Proc. Natl. Acad. Sci. USA 118(21), e2104547118 (2021).", "volume": "118", "year": "2021" } ], "reference-count": 20, "references-count": 20, "relation": {}, "resource": { "primary": { "URL": "https://www.nature.com/articles/s41598-022-24683-8" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Multidisciplinary" ], "subtitle": [], "title": "A prospective, randomized, open-label trial of early versus late povidone-iodine gargling in patients with COVID-19", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "volume": "12" }